HP
HLB Pep Co., Ltd. (formerly Anygen Co., Ltd.)
CDMO · Gwangju, South Korea
GMPISO
Gwangju MFDS ordered a one-month suspension of desmopressin and leuprorelin API manufacturing at the Jangseong plant, announced 2025-09-15 (missing 2022-2023 annual product quality reviews). See the FDA enforcement tracker
Overview
HLB Pep was founded in 2000 as Anygen and took its current name in 2025. It is listed on KOSDAQ. It makes generic peptide APIs, contract GMP peptides, custom and catalog peptides. Its history page cites Korea MFDS GMP approval for peptide APIs in 2011, a GMP finding for its Osong plant in 2020, and Japanese MHLW foreign-manufacturer accreditation in 2010. The FDA DMF list shows active Type II DMFs for ganirelix acetate (as Anygen) and arginine-vasopressin acetate (as HLB Pep), plus one for leuprorelin. In September 2025 the Gwangju MFDS office suspended desmopressin and leuprorelin API production at its Jangseong plant for one month over missing annual quality reviews.
Capabilities
- Ganirelix and vasopressin API
- Generic peptide APIs
- Contract GMP peptide manufacturing
- Custom and catalog peptides
Quality signals
| GMP evidence | Yes |
|---|---|
| Certificates of analysis | Not found |
| Third-party testing | Not found |
| ISO certification | Yes |
| Makes own product | Yes, in-house production |